**Piramal Pharma Limited (PPLPHARMA) Investment Report**

**Date:** December 20, 2024


**1. Company Overview:**

Piramal Pharma Limited (PPLPHARMA) operates in the Pharmaceuticals industry.  It was listed on the exchange on October 19, 2022.  Further details on its specific market positioning within the sector are needed for a complete analysis.


**2. Market Data Analysis:**

| Metric                     | Value          | Notes                                      |
|-----------------------------|-----------------|----------------------------------------------|
| Current Price               | ₹251.30        |                                              |
| Percentage Change (PChange) | -3.94%         | Negative daily change indicates downward pressure |
| Pre-Open Activity          | ₹264.40 (IEP)  | Higher pre-open price than current price suggests selling pressure during the trading session. |
| Week High                   | ₹307.90        | Significant high suggests recent upward momentum, now reversed. |
| Week Low                    | ₹114.35        | Significant low indicates considerable volatility. |
| VWAP                        | ₹260.81        | Volume Weighted Average Price is higher than the current price. |
| Sector PE                   | 0               | Data unavailable.  Requires further investigation. |
| Symbol PE                   | 0               | Data unavailable. Requires further investigation. |
| Delivery Percentage         | 24.72%         | Relatively low delivery percentage suggests a significant portion of trading was speculative. |
| Market Depth                | Poor            |  Order book data shows zero buy and sell quantities at all price levels, indicating poor liquidity. This is a significant risk factor. |


**3. Financial Performance:**

The provided financial data shows a mixed picture. While revenue has generally increased over the past five quarters, the company has consistently reported losses (negative profit after tax and negative EPS).  Key financial ratios (e.g., profit margins, return on equity) are missing and crucial for a comprehensive assessment.

| Quarter       | Revenue (₹) | Expenses (₹) | Profit After Tax (₹) | EPS (₹) |
|---------------|-------------|-------------|-----------------------|---------|
| Q2 FY25 (Jul-Sep 2024) | 139,077     | 111,506     | 21,006                | 1.59    |
| Q1 FY25 (Apr-Jun 2024) | 109,996     | 98,830      | 8,527                 | 0.64    |
| Q4 FY24 (Jan-Mar 2024) | 157,849     | 121,582     | 27,308                | 2.06    |
| Q3 FY24 (Oct-Dec 2023) | 105,725     | 96,759      | 7,434                 | 0.56    |
| Q2 FY24 (Jul-Sep 2023) | 108,332     | 98,713      | 7,716                 | 0.61    |


**4. Corporate Actions and Announcements:**

* **Dividend:** A dividend of ₹0.11 per share was declared with an ex-date of July 12, 2024.
* **Rights Issue:** A rights issue (5:46) at a premium of ₹71 was conducted with an ex-date of August 2, 2023.
* **Recent Announcements:** Several announcements related to litigation, guarantees, financial results clarifications, and investor meetings suggest potential ongoing challenges and uncertainty.


**5. Shareholding Patterns:**

| Quarter       | Promoter & Promoter Group (%) | Public (%) | Shares held by Employee Trusts (%) | Total (%) |
|---------------|-----------------------------|------------|---------------------------------|-----------|
| 30-Sep-2023   | 35.02                        | 64.60      | 0.38                           | 100.00    |
| 31-Dec-2023   | 35.02                        | 64.60      | 0.38                           | 100.00    |
| 31-Mar-2024   | 35.02                        | 64.61      | 0.37                           | 100.00    |
| 30-Jun-2024   | 34.95                        | 64.58      | 0.47                           | 100.00    |
| 30-Sep-2024   | 34.95                        | 64.61      | 0.45                           | 100.00    |

Promoter holding has slightly decreased over the past year, while public holding remains relatively stable.


**6. Volatility and Risk Assessment:**

The stock exhibits high volatility, as evidenced by the significant difference between the week's high and low. The low delivery percentage and poor market depth further amplify the risk.  The lack of sector and symbol PE ratios prevents a proper risk-reward assessment based on valuation.  The consistent losses reported in the financial statements are a major red flag.


**7. Advantages of Buying the Stock:**

* Relatively stable shareholding pattern.
* Recent revenue growth (though profitability remains negative).


**8. Disadvantages and Risks:**

* High volatility and low liquidity.
* Consistent losses and negative EPS.
* Missing key financial ratios hindering a complete assessment.
* Several announcements indicating potential legal and financial challenges.
* Poor market depth.


**9. Investment Horizon Recommendations:**

* **Short-Term (less than 3 months): Don't Buy.** The high volatility, negative price momentum, and poor market depth make a short-term investment extremely risky.

* **Medium-Term (3 to 12 months): Don't Buy.**  While revenue shows some growth, the consistent losses and lack of profitability are major concerns.  Further investigation into the announcements and financial ratios is needed before considering any investment.

* **Long-Term (1 year and beyond): Don't Buy.**  The fundamental issues of profitability and the lack of clear long-term growth strategy make a long-term investment too risky at this time.


**10. Stock and Analysis Scoring:**

**Stock Score (out of 10): 3/10**

* Financial Health: 2/10 (Consistent losses, missing key ratios)
* Market Performance: 2/10 (High volatility, negative price momentum, low delivery percentage)
* Volatility and Risk: 1/10 (High volatility, low liquidity, significant risks)
* Corporate Actions and Governance: 5/10 (Dividend paid, but rights issue and announcements raise concerns)
* Shareholding Patterns: 7/10 (Relatively stable shareholding)

**Analysis Score (out of 10): 7/10**

* Completeness and utilization of data: 8/10 (Most data used effectively, but some key data missing)
* Accuracy and clarity of analysis: 7/10 (Analysis is clear, but limited by missing data)
* Professional formatting: 8/10 (Report is well-structured and easy to read)


**11. Professional Recommendation Summary:**

Based on the analysis of available data, PPLPHARMA is not recommended for investment in the short, medium, or long term. The high volatility, consistent losses, poor market depth, and several concerning announcements outweigh any potential positive aspects.  Further investigation into the company's financials, sector positioning, and the nature of the announcements is strongly recommended before considering any investment.  The missing key financial ratios significantly limit the scope of this analysis.
